Literature DB >> 18283405

Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab.

Ghassan El Maalouf, Emmanuel Mitry, Alexis Lacout, Astrid Lièvre, Philippe Rougier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18283405     DOI： 10.1007/s00415-008-0692-2

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  12 in total

1.  Soluble endoglin contributes to the pathogenesis of preeclampsia.

Authors:  Shivalingappa Venkatesha; Mourad Toporsian; Chun Lam; Jun-ichi Hanai; Tadanori Mammoto; Yeon M Kim; Yuval Bdolah; Kee-Hak Lim; Hai-Tao Yuan; Towia A Libermann; Isaac E Stillman; Drucilla Roberts; Patricia A D'Amore; Franklin H Epstein; Frank W Sellke; Roberto Romero; Vikas P Sukhatme; Michelle Letarte; S Ananth Karumanchi
Journal:  Nat Med       Date:  2006-06-04       Impact factor: 53.440

Review 2.  Angiogenic imbalance in the pathophysiology of preeclampsia: newer insights.

Authors:  Yuval Bdolah; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  Semin Nephrol       Date:  2004-11       Impact factor: 5.299

Review 3.  Angiogenic factors and preeclampsia.

Authors:  May Lee Tjoa; Richard J Levine; S Ananth Karumanchi
Journal:  Front Biosci       Date:  2007-01-01

4.  Is angiogenesis an organizing principle in biology and medicine?

Authors:  Judah Folkman
Journal:  J Pediatr Surg       Date:  2007-01       Impact factor: 2.545

5.  Reversible posterior leukoencephalopathy syndrome and bevacizumab.

Authors:  Peter Glusker; Larry Recht; Barton Lane
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

6.  Reversible posterior leukoencephalopathy syndrome and bevacizumab.

Authors:  Cevher Ozcan; Stuart J Wong; Parameswaran Hari
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

7.  Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.

Authors:  Jeffrey A Allen; Ashish Adlakha; Peter R Bergethon
Journal:  Arch Neurol       Date:  2006-10

8.  Brain stem hypertensive encephalopathy evaluated by line scan diffusion-weighted imaging.

Authors:  Motonori Nagata; Masayuki Maeda; Hirokazu Tsukahara; Stephan E Maier; Ken Takeda
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

9.  Circulating angiogenic factors and the risk of preeclampsia.

Authors:  Richard J Levine; Sharon E Maynard; Cong Qian; Kee-Hak Lim; Lucinda J England; Kai F Yu; Enrique F Schisterman; Ravi Thadhani; Benjamin P Sachs; Franklin H Epstein; Baha M Sibai; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  N Engl J Med       Date:  2004-02-05       Impact factor: 91.245

10.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245
View more
  9 in total

1.  Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.

Authors:  Christina A K Kim; Julie Price-Hiller; Quincy S Chu; Keith Tankel; Ron Hennig; Michael B Sawyer; Jennifer L Spratlin
Journal:  Invest New Drugs       Date:  2014-05-23       Impact factor: 3.850

2.  Reversible posterior leukoencephalopathy syndrome associated with concurrent bevacizumab, gemcitabine, and oxaliplatin for cholangiocarcinoma.

Authors:  Yongen Chang; Gilbert Mbeo; Susan J Littman
Journal:  J Gastrointest Cancer       Date:  2012-09

Review 3.  Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.

Authors:  Camille Tlemsani; Olivier Mir; Pascaline Boudou-Rouquette; Olivier Huillard; Karin Maley; Stanislas Ropert; Romain Coriat; François Goldwasser
Journal:  Target Oncol       Date:  2011-11-17       Impact factor: 4.493

4.  Posterior Reversible Encephalopathy Syndrome and Anti-Angiogenic Agents: A Case Report.

Authors:  Filipe Manuel Dos Reis Simões da Silva; Peter Mike Burgos Pêgo; Maria Cristina Henriques Vendrell; Maria João de Azevedo Batalha Ferreira Dos Santos Farias; Ângela Cátia Ribeiro Timóteo; Maria Cristina Martins da Costa; Isabel Maria Monteiro Barbosa Moreira Cravo; Fernando Manuel Ribeiro Gomes
Journal:  Neuroophthalmology       Date:  2011-01-16

5.  Bevacizumab-mediated interference with VEGF signaling is sufficient to induce a preeclampsia-like syndrome in nonpregnant women.

Authors:  Sarah N Cross; Elena Ratner; Thomas J Rutherford; Peter E Schwartz; Errol R Norwitz
Journal:  Rev Obstet Gynecol       Date:  2012

6.  Tumour-like presentation of atypical posterior reversible encephalopathy syndrome with prominent brainstem involvement.

Authors:  Vincenzo Di Stefano; Marianna Gabriella Rispoli; Marco Onofrj; Maria Vittoria De Angelis
Journal:  BMJ Case Rep       Date:  2020-01-08

7.  Posterior reversible encephalopathy syndrome in neuro-malaria.

Authors:  Alexis Lacout; Celine Guidoux; Robert Yves Carlier
Journal:  Indian J Radiol Imaging       Date:  2010-08

8.  Atypical reversible leucoencephalopathy syndrome after bevacizumab/folfox regimen for metastatic colon cancer.

Authors:  Narimane Salmi; Ibrahim Elghissassi; Khadija Bellahammou; Asmaa Lakhdissi; Hind Mrabti; Hassan Errihani
Journal:  Case Rep Oncol Med       Date:  2014-10-21

9.  Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study.

Authors:  Astrid Lièvre; Emmanuelle Samalin; Emmanuel Mitry; Eric Assenat; Christine Boyer-Gestin; Céline Lepère; Jean-Baptiste Bachet; Fabienne Portales; Jean-Nicolas Vaillant; Marc Ychou; Philippe Rougier
Journal:  BMC Cancer       Date:  2009-09-28       Impact factor: 4.430
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.